How I treat AL amyloidosis

Area of Science:

• Hematology
• Oncology
• Nephrology

Background:

• Systemic light chain (AL) amyloidosis presents diagnostic and therapeutic challenges for hematologists.
• Toxic light chains form amyloid deposits, causing progressive multiorgan dysfunction, often diagnosed late.
• Hematologists can identify AL amyloidosis presymptomatically in high-risk monoclonal gammopathy patients.

Purpose of the Study:

• To review current diagnostic and therapeutic strategies for AL amyloidosis.
• To highlight the impact of recent clinical trials on evidence-based treatment.
• To emphasize personalized therapy and early monitoring for improved outcomes.

Main Methods:

• Review of recent randomized clinical trials in AL amyloidosis.
• Analysis of diagnostic biomarkers and organ involvement.
• Evaluation of novel therapeutic agents and treatment protocols.

Main Results:

• Daratumumab-bortezomib combination emerges as a new standard-of-care for newly diagnosed AL amyloidosis.
• This combination induces rapid, deep responses, leading to significant organ response rates.
• New drugs enable personalized therapy, reduced toxicity, and better patient outcomes.

Conclusions:

• Prompt diagnosis and tailored therapy are crucial for managing AL amyloidosis.
• Evidence-based treatments, particularly daratumumab-bortezomib, have transformed patient care.
• Clinical trial participation is recommended for optimal patient management and outcomes.